Brokerages predict that OraSure Technologies, Inc. (NASDAQ:OSUR) will post $0.07 earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for OraSure Technologies’ earnings. OraSure Technologies also reported earnings of $0.07 per share during the same quarter last year. The business is expected to report its next earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that OraSure Technologies will report full-year earnings of $0.44 per share for the current financial year, with EPS estimates ranging from $0.40 to $0.47. For the next fiscal year, analysts anticipate that the business will report earnings of $0.31 per share, with EPS estimates ranging from $0.30 to $0.31. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.04. OraSure Technologies had a net margin of 15.38% and a return on equity of 11.64%. The business had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $31.19 million. During the same quarter in the previous year, the firm posted $0.04 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year.

Several brokerages have recently commented on OSUR. Zacks Investment Research downgraded shares of OraSure Technologies from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 1st. Jefferies Group LLC raised their price objective on shares of OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, May 4th. Canaccord Genuity set a $12.00 price objective on shares of OraSure Technologies and gave the company a “buy” rating in a research report on Thursday, February 9th. Finally, Raymond James Financial, Inc. upgraded shares of OraSure Technologies from a “market perform” rating to an “outperform” rating and set a $11.25 price objective on the stock in a research report on Thursday, February 9th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $12.04.

Shares of OraSure Technologies (NASDAQ:OSUR) traded down 1.13% during midday trading on Tuesday, reaching $14.94. 387,082 shares of the company’s stock were exchanged. The stock has a market cap of $850.52 million, a price-to-earnings ratio of 28.62 and a beta of 1.44. The firm has a 50 day moving average of $13.14 and a 200-day moving average of $10.29. OraSure Technologies has a one year low of $5.57 and a one year high of $15.72.

In related news, CEO Douglas A. Michels sold 361,216 shares of OraSure Technologies stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $15.08, for a total transaction of $5,447,137.28. Following the completion of the transaction, the chief executive officer now directly owns 881,620 shares of the company’s stock, valued at approximately $13,294,829.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Douglas A. Michels sold 209,800 shares of OraSure Technologies stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $15.01, for a total transaction of $3,149,098.00. Following the transaction, the chief executive officer now directly owns 782,025 shares of the company’s stock, valued at $11,738,195.25. The disclosure for this sale can be found here. Insiders sold a total of 1,067,346 shares of company stock valued at $15,121,802 over the last three months. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in OSUR. BlackRock Inc. boosted its position in OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after buying an additional 7,737,261 shares in the last quarter. Renaissance Technologies LLC boosted its position in OraSure Technologies by 22.3% in the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock worth $66,357,000 after buying an additional 934,700 shares in the last quarter. Vanguard Group Inc. boosted its position in OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock worth $57,752,000 after buying an additional 1,037,439 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in OraSure Technologies by 15.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,890,048 shares of the medical instruments supplier’s stock worth $37,368,000 after buying an additional 395,374 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in OraSure Technologies by 127.2% in the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock worth $20,347,000 after buying an additional 881,132 shares in the last quarter. 79.51% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/05/16/orasure-technologies-inc-osur-expected-to-post-earnings-of-0-07-per-share.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

5 Day Chart for NASDAQ:OSUR

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.